GSK, Abbott drug combo kills triple-negative breast cancer in mice

Combining two separate drugs made by GlaxoSmithKline ($GSK) and Abbott ($ABT) appeared to defeat a particularly lethal version of breast cancer cells in lab and mouse studies. The GSK drug--lapatinib (Tykerb), a kinase inhibitor--is approved to treat human epithelial growth factor receptor 2 (HER2) positive breast cancers and used in at least one other treatment combination. Abbott's veliparib is a PARP inhibitor in clinical trials for a number of cancers including breast cancer. What's novel here is scientists at the University of Alabama at Birmingham are exploring the combined drugs as a treatment for triple-negative breast cancer. More from FierceBiotechResearch


Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.